12/06/2025
🌟 Now Enrolling: Alzheimer’s Agitation Research Study (BMS ADAGIO-2 Study) 🌟
Agitation is one of the most common and disruptive symptoms of Alzheimer’s disease — affecting up to 76% of patients, according to the study overview.
If you or someone you love is experiencing agitation related to Alzheimer’s, the ADAGIO-2 Study may be an option. This clinical trial is testing an oral investigational medication to see if it can safely help reduce agitation.
Who may qualify?
• Adults 55–90 years old
• Diagnosed with Alzheimer’s disease
• Experiencing physical and/or verbal agitation for at least 2 weeks — such as hitting, kicking, shouting, pacing, wandering, throwing things, or resisting care.
• Must have a caregiver or study partner who can attend visits and assist with study activities.
What to expect:
📅 Study participation lasts about 5 months, including clinic visits and phone check-ins.
💊 Participants may receive the investigational oral medication or placebo.
🧪 All study-related care, tests, and evaluations are provided at no cost.
🚗 Participants and caregivers may be reimbursed for time and travel.
Participation is voluntary, and you may leave the study at any time.
📞 Call Sharlin Research today: 417-238-3301
🌐 Learn more or view our active studies: SharlinResearch.com